Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services

The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract for ClonoSEQ Measurable Residual Disease (MRD) testing services. The contract will be awarded to Adaptive Biotechnologies Corporation, as they are the sole source provider of clonoSEQ MRD testing within the United States. The services are required by the VA Northeast Ohio Healthcare System (VANEOHS), Pathology and Laboratory Medicine Service (PALMS). The scope of work includes molecular minimal residual disease (MRD) testing services utilizing the clonoSEQ Assay. • The clonoSEQ Assay is a proprietary, patented molecular test developed and performed exclusively by Adaptive Biotechnologies. • The contract is being awarded under Simplified Acquisition Procedures and the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. • The associated NAICS code for this is 621511, Size Standard is $41.5 Million. • The Product Service Code (PSC) is Q301.